Products/Programs
The Company also is developing back-up and follow-on compounds to CX717. One compound, CX1739, has begun preclinical development, and if it successfully completes these studies, will be tested in Phase I in 4Q 2008. Further back-up and follow-on molecules are being selected for preclinical development.
| Name |
Low or High Impact? |
Indication |
Description |
Status |
| CX717 |
Low Impact |
Alzheimer’s disease |
A double-blind, placebo-controlled Phase IIa pilot study is ongoing in mild-to-moderate Alzheimer’s disease, with each patient receiving psychometric tests and PET scans. |
Phase IIa PET imaging study ongoing |
| |
|
Respiratory Depression |
Preclinical data in rats and pigs suggests CX717 prevents and reverses respiratory depression following administration of opiates such as fentanyl, or barbiturates. |
Two Phase IIa pilot studies have been initiated in Europe. Top-line results are expected late June/July 2008. |
| CX1739 |
Low Impact |
ADHD, Alzheimer’s Disease |
Phase I studies ongoing |
Phase I development |
| CX1942 |
Low Impact |
Respiratory Depression |
IND-enabling studies are being initiated. |
IND-enabling studies ongoing. |
| CX1796 |
Low Impact |
ADHD, Respiratory depression, Alzheimers’ Disease |
IND-enabling studies are being initiated. |
IND-enabling studies ongoing. |
| ORG24448 |
Low Impact |
Schizophrenia |
Out-licensed to Schering-Plough (formerly Organon). |
Phase II |
| Depression |
Phase II |
| ORG26576 |
Low Impact |
Depression
ADHD |
Out-licensed to Schering-Plough (formerly Organon). |
Phase II |
| CX1837 & other High Impact Molecules |
High Impact |
(TBA) |
Late-stage lead optimization ongoing. |
Selection of compound for IND-enabling studies estimated 3Q08. |
| Milestone |
Est. Timelines |
RD-01: Single dose
- IMPD Filing
- Initiation
- Completion |
Q4, 2007
Q1, 2008
Q3, 2008 |
RD-02: Dose Ranging
- IMPD Filing
- Initiation
- Completion |
Q4, 2007
Q1, 2008
Q2, 2008 |
|